Dr. A Velumani, Thyrocare's founder, advises parents against overindulging their children, emphasizing the crucial roles of ...

Thyrocare founder Dr. A Velumani sparks debate with his viral video criticizing the over-scheduling of city children. He ...

What struck him most was Redcliffe Labs’ pace. “Had an hour of interaction on how it is going for @Redcliffe Labs. I hear a ...

Franchise-led expansion has been the key driver behind Thyrocare’s strong Q1 performance, with CEO Rahul Guha attributing the 23% revenue growth and 60% profit surge to the addition of 1,500 new ...

Thyrocare Technologies Limited reported a 62% year-on-year increase in profit after tax (PAT) to ₹38.06 crore for the quarter ended June 30, 2025. The company's revenue from operations grew by 23% to ...

Dr A Velumani urged parents to rethink the pressures of over-scheduling in urban childhoods, advocating instead for a slower ...

Thyrocare Technologies shares zoomed 12.66 per cent in trade, hitting a 52-week high at ₹1,356.95 per share on the BSE.

While Thyrocare Technologies doesn't seem to have gained much on the EBIT line, at least earnings remain stable for now. There's no doubt that we learn most about debt from the balance sheet.

Thyrocare’s consolidated net profit rose 59.9% to INR 38.3 Cr in Q1 FY26 from INR 23.9 Cr in the year-ago quarter ...

Net Sales at Rs 178.89 crore in June 2025 up 24.55% from Rs. 143.63 crore in June 2024. Quarterly Net Profit at Rs. 36.05 crore in June 2025 up 43.34% from Rs. 25.15 crore in June 2024. EBITDA stands ...

Thyrocare Technologies surged 11.30% to Rs 1,340.55 after the healthcare service provider reported a 61.07% increase in consolidated net profit to Rs 38.93 crore on a 23.02% rise in revenue from ...

Thyrocare Technologies has a P/E ratio of 29.82, based on the last twelve months. In other words, at today's prices, investors are paying ₹29.82 for every ₹1 in prior year profit.